Aurinia Q1 net revenue $21.6M, net loss $37.6M; FY22 guidance reaffirmed

Aurinia Pharmaceuticals Inc.

2022-Q1 EPS reported -$0.27 revenue$21,625,000

Net product revenue $21.6M (Q1 2021: $0.9M); net loss $37.6M ($0.27/shr) vs $50.4M ($0.40) YoY.
Maintains FY2022 LUPKYNIS revenue guidance $115-$135M, representing 150-200% growth over FY2021.
Patients on LUPKYNIS reached ~1,071 at March 31, 2022, up 21% from 884 at December 31, 2021.
EMA review on track; European Commission decision expected in second half of 2022.
Cash, cash equivalents and investments $418.8M at March 31, 2022, down from $466.1M at year-end 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.